Dealings in Clinigen shares are expected to commence on AIM at 8.00am on Tuesday 25 September 2012, under the ticker symbol CLIN





Clinigen is a rapidly-growing specialty pharmaceutical and services company, with one clear aim: to deliver the right drug to the right patient at the right time.




To achieve our aim, we have built a group of complementary businesses which can operate efficiently in a complex global regulatory environment and which can ensure that precious medicines are delivered securely and effectively, wherever they are needed. Through three businesses, Clinigen SP, Clinigen GAP, and Clinigen CTS, we acquire, license and revitalise niche, hospital-only critical care medicines, and source and supply our own and other pharmaceutical companies’ products, whether to meet unmet medical needs or for use in clinical trials.





Clinigen Clinical Trials Supply (CTS):

We use our global expertise, systems and relationships to source and manage the supply of commercial medicines to pharmaceutical companies for use exclusively in clinical trials. This requires excellent knowledge of the global pharmaceutical market, the regulatory processes and customs authorities of countries all over the world, along with a high tech supply chain with guaranteed quality and safety standards that can deliver swiftly.

Clinigen Global Access Programs (GAP):

On behalf of pharmaceutical and biotech companies, we manage essential programs that provide access to critical medicines for physicians and their patients all over the world. But what is a Global Access Program? Known by many terms from ‘expanded access’ and ‘named patient’ to ‘compassionate use’ and ‘early access’, a global access program enables physicians to access treatments that are not available in their own country for patients with an unmet medical need. Wherever they are, we can deliver treatments quickly, efficiently and, most importantly, ethically.

Clinigen Specialty Pharmaceuticals (SP):

We acquire niche medicines that don’t fit into the portfolio of larger pharmaceutical companies. These are typically hospital-only treatments for rare or life-threatening diseases, and we specialise in revitalising them – finding new treatment areas; new markets where we can get them licensed; or, potentially, new formulations. All the while, we’re ensuring that patients already using the medicine continue to get the treatment they need, while the company whose product we have acquired can feel confident that its reputation is being well looked after.

We are currently 100+ people, headquartered in Burton-on-Trent in the UK, with facilities in Philadelphia, US, and Tokyo, Japan, and an office in London. With a customer services team who speak over 19 languages between them, our clients from all over the world find us easy to do business with, while doctors and pharmacists find us a valuable source of information about how to access the medicines they need for their patients.




http://www.clinigen.co.uk/

Investors chronicle - Clinigen lists on AimMajor Alternative Investment Market (Aim) floats for medical companies have been a rare sight over the past few years as the credit crunch and dearth of private equity deals combined to starve the market of new entrants. That is about to change with the listing of Clinigen, a medical company that sources products for medical trials, in an IPO that could value the company at £170m.

Clinigen was established by serial entrepreneur Andrew Leaver, who is also selling most of his stake, and specialises in delivering secondary drugs to clinical trials and organising the logistics for studies involving thousands of patients across many locations. It also buys up drugs that are too small for big pharma companies to bother with and sells them into new markets, as a recent deal with AstraZeneca for HIV drug Foscavir illustrates. Sales to 30 June were £82.1m, with cash profits of £17.3m. Chief executive Peter George said the IPO would give the company a war chest of £25m for product acquisitions; it has about 27 potential targets.

IC VIEW:
Clinigen is unique in the sector, as far as we can tell, in combining a variety of outsourcing services with direct product sales. The free float will be about 60-70 per cent. One to watch.

Clinigen is now officially number 1 in the Fast Track 100
Clinigen is the fastest-growing private company in the UK. We’re delighted to be ranked first in the Sunday Times Virgin Fast Track 100, which was published on December 4th 2011.

This award recognizes the exceptional sales growth we have achieved over the past three years. It also sets a high benchmark for the future success of the Clinigen Group. We’re looking forward to fresh new challenges as we evolve our business in the years ahead.

Major interest in shares

http://www.moneyam.com/action/news/showArticle?id=4453273

Clinigen had its £50 million market debut on the 25th Sept . The 135million cap, which provides pharmaceuticals and related services from its offices in the UK, US and Japan, is using the proceeds of the first pharmaceutical initial public offering in London for 5 years to build a £25 million war chest to expand its product range.
Chief executive Peter George is looking at 27 potential acquisitions involving niche hospital drugs that he believes the group can revitalise. Five of these discussions are at advanced stages and George hopes to announce one deal in the next few months. Any transaction would compliment the groups antiviral drug Foscavir,bought from AstraZeneca in 2010.
Interest in the company has been strong, Shareholders put £50 million in the Numis Securities-managed placing and the price jumped by 10p to 174p hours after the shares started trading on the Aim.
Clinigen, which names 13 of the worlds top 20 pharmaceutical companies by sales among its clients, has grown its revenues by 242% since it was established in 2010.
The topline jumped 135% to £82.1 million in the year to July 2012 alone. This generated earnings before interest taxes depreciation and amortisation (EBITDA) of £17.3 million, a year-on-year increase of 109%
Driving these figures is the organic growth of its US business, which generated sales of more than $50 million last year, up from $10 million in the prior 12 month period.
Arobust balance sheet leaves Clinigen with plenty of scope to implement its strategy.
It has just £1.6 million of shareholders loans, which George expects to clear by year end.

http://www.edisoninvestmentresearch.co.uk/researchreports/Clinigen011112QV.pdf

A buy in this weeks shares mag - Revenues have increased 242% since 2010 driven by investment in its sales teams.

up 7.5%

Tipped I hear by SCSW this weekend.

A buy in this weeks share mag. The proceeds from the Sept flotation have helped to create a £20m war chest, which includes cash and £10m of debt from the Royal Bank of Scotland. Chief executiver Peter George is hoping to add a second treatment to his sales forces in the UK, the USA and Japan by the end of the year.
Only established in 2010, Clinigen is expected to record £97.1m in sales for its fiscal year to June 2013 and £17m in pre-tax profit. That points to earnings per share of 14.5p, which leaves the stock on a tempting earnings multiple of 14.1 times .
The healthy balance sheet could even fund a dividend and further acquisitions should complement strong organic growth.

A buy in this weeks IC mag.

RNS Number : 7451W

Clinigen Group plc

31 January 2013




RNS Announcement:





31 January 2013



Clinigen Group plc



Notification of Interim Results Date



Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and pharmaceutical services business, will be announcing its interim results for the period ended 31 December 2012 on Wednesday, 27 February 2013.

There will be an analyst meeting on 27 February 2013 at the offices of College Hill, The Registry, Royal Mint Court, London EC3N 4QN. Analysts who wish to attend should contact Stefanie Bacher on +44 (0)20 7457 2020 or email Clinigen@CollegeHill.com to register.

On the move

Clinigen declares maiden divi after impressive stock market debut
By Benjamin Chiou | Sharecast – 1 hour 36 minutes ago.. .





LONDON (ShareCast) - Clinigen, the speciality pharmaceuticals company which listed on the AIM market last autumn, saw shares surge on Wednesday after the firm reported a massive jump in first-half sales and declared a maiden dividend.

Sales soared by 86% from £32.7m to £61.0m in the six months to December 31st, while underlying profit before tax surged 54% from £6.3m to £9.7m.

Chief Executive Peter George told Sharecast that the company is "very pleased" with its trading performance in the first six months of the year after successful stock-market debut in September.

The board decided to declare the company's first interim dividend of 0.6 per share and said it is targeting progressive dividend growth.

Shares were up 11.21% at 234.65p by 11:12 on Wednesday morning, compared with the placing price of 164p.

George hailed "significant organic growth from all three operating divisions", but highlighted the standout performance of the Clinical Trial Supply (CTS) division, the dominant revenue generator of Clinigen.

CTS, which provides commercial medicines for use in clinical trials, saw an impressive 113% sales increase driven by its expansion into the US markets and new business wins. However, George did say that CTS's second half growth will likely not be as strong, though this is to be expected given the "lumpiness" of seasonality in the industry.

Meanwhile, the Global Access Programs (GAP (NYSE: GPS - news) ) division is on track to deliver three-fold growth this year, George said, after a whopping 222% increase in sales in the first half. GAP provides early-market access to medicines before regulatory approval or provides drugs to patients after discontinuation or withdrawal. It currently is the exclusive supplier of 32 drugs across the world.

The third division, Speciality Pharmaceuticals (SP), targets niche, hospital-only, end-of-lifecycle drugs previously owned by large pharma firms, by acquiring or in-licensing them. The company's first product is Foscavir, acquired from AstraZeneca (NYSE: AZN - news) in 2010, which achieved 22% sales growth in the first half.

Group cash and cash equivalents totalled £22.3m by the end of the half, up from just £5.2m at June 30th 2012.

Optimistic outlook

The company said that trading in the second half of the financial year has "started well".

George told Sharecast that he is confident that full-year sales would beat current market forecasts due to the strength in CTS, though expected margin reductions will likely mean that the bottom line would be in line with estimates.

He said that there is potential for good synergies between the three divisions, saying that "one plus one plus one is greater than three".

Clinigen Group: Numis ups target price from 240p to 265p, while its buy recommendation is reiterated

Clinigen Group and Theravance Entered into Excl...
BZW
Clinigen Group and Theravance Entered into Exclusive Commercialization Agreement in the EU for Antibacterial VIBATIV®


Clinigen Group plc


Clinigen and Theravance Announce Exclusive Commercialization Agreement in the EU for VIBATIV® (telavancin)

Clinigen Group plc (LSE: CLIN) (AIM: CLIN) and Theravance, Inc. (NASDAQ: THRX) today announced that they have entered into an exclusive commercialization agreement in the European Union (EU) and certain other countries located in Europe for VIBATIV® (telavancin) for the treatment of nosocomial pneumonia (hospital-acquired), including ventilator-associated pneumonia, known or suspected to be caused by methicillin resistant Staphylococcus aureus (MRSA) when other alternatives are not suitable. VIBATIV® is a bactericidal, once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as MRSA.

Under the terms of the agreement, Theravance has granted Clinigen exclusive commercialization rights to VIBATIV® in the EU and certain other European countries (including Switzerland and Norway). In exchange, Theravance will receive a $5 million upfront payment from Clinigen and is entitled to receive tiered royalties on net sales of VIBATIV®, ranging from 20% to 30%. The agreement has a term of at least 15 years, with an option to extend exercisable by Clinigen.

��SWe are pleased to have Theravance, a leader in antibiotic development, as a license partner,⬝ said Peter George, Chief Executive Officer of Clinigen. ��SThis agreement is of strategic importance to us as it not only strengthens our anti-infective offering with a product that has patent protection into the next decade, but it is an exciting opportunity to commercialize VIBATIV® and Foscavir® while leveraging their operational synergies. VIBATIV® is a second product for Clinigen��"s Specialty Pharmaceuticals (SP) portfolio, complementing the division��"s anti-viral product, Foscavir®.⬝

��SWe are very excited to partner with Clinigen and we believe that its innovative business model and experience in specialty pharmaceuticals provide an ideal platform to maximize the growth opportunity for VIBATIV®,⬝ said Rick E Winningham, Chief Executive Officer of Theravance. ��SWe look forward to working with Clinigen in making VIBATIV® available to patients with nosocomial pneumonia in the EU."

Gone long.

http://www.investegate.co.uk/clinigen--clin-/bus/clinigen-group-and-theravance-entered-into-excl---/20130311070000Z6247/

Should get these figures upgraded over next 48 hours.


Date Rec Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Numis Securities Ltd
27-02-13 BUY 17.20 15.40 1.80 19.80 17.30 2.30

2013 2014
Pre-tax (£) EPS (p) DPS (p) Pre-tax (£) EPS (p) DPS (p)

Consensus 17.20 15.40 1.80 19.80 17.30 2.30
1 Month Change 0.20 0.90 -0.05 0.20 0.60 0.07
3 Month Change 0.20 0.90 -0.05 0.20 0.60 0.07


GROWTH
2012 (A) 2013 (E) 2014 (E)
Norm. EPS 52.96% 92.58% 12.34%
DPS % % 27.78%

INVESTMENT RATIOS
2012 (A) 2013 (E) 2014 (E)

EBITDA £11.76m £12.30m £20.10m
EBIT £10.54m £17.20m £19.40m
Dividend Yield % 0.71% 0.90%
Dividend Cover x 8.56x 7.52x
PER 31.83x 16.53x 14.71x
PEG 0.60f 0.18f 1.19f
Net Asset Value PS 17.64p p p

Clinigen Group: Numis revises target price from 265p to 310p and stays with its buy recommendation.

CLIN - Numis Buy; Ups target to 310p

Speciality pharma firm Clinigen (CLIN:AIM) improved 6.9% to 272p as management delivered on its promise to add a new drug to its portfolio within six months of the £210 million cap’s listing on Aim. The company has secured the European rights to Vibativ, a treatment for pneumonia caused by MRSA, from US firm Theravance. Charles Weston at Numis expects sales to commence in the first half of 2014 and expects the treatment to generate up to £6 million a year.

A buy in this weeks SM - Antibiotic resistance is very much in the news, which adds a timeliness to a deal between clinical product supply specialist Clinigen and US biotech company Theravance. Clinigen has tied up the European rights for vibativ, a treatment for drug-resistant pneumonia resulting from an MRSA super-bug infection.
For $5m (£3.3m) upfront fee, Clinigen has acquired the EU rights to Vibativ, as well as rights for Switzerland and Norway, and will pay a royalty to Taheravance of between 20% -30%, dependiing on sales.